Supply Levofloxacin heMihydrate Raw Materials powder

CAS:138199-71-0

MF:C43H63NO11

MW:769.97

EINECS:815-979-7

Specification: 99% min Levofloxacin heMihydrate

Sample:Levofloxacin heMihydrate powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:light yellow

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Levofloxacin heMihydrate of Usage and Synthesis.

Levofloxacin semi-hydrate can be used as a drug reference standard to determine the analytes in pharmaceutical preparations by various chromatographic and spectrophotometric techniques.

These secondary standards are qualified certified reference substances. They are suitable for use in a variety of analytical applications, including but not limited to drug release detection, drug method development for qualitative and quantitative analysis, food and beverage quality control testing, and other calibration requirements.

Uses of Levofloxacin heMihydrate.

1. Infection of the genitourinary system, including simple and complex urinary tract infection prostatitis, gonorrhea, urethritis, cervicitis, etc.

2. Respiratory tract infections include acute episodes of bronchial infection caused by gram-negative bacilli and lung infection.

3. Gastrointestinal infection.

4. Typhoid fever.

5. For bone and joint infections, levofloxacin is a commonly used anti-inflammatory drug in clinical practice. It is a broad-spectrum antibiotic with strong antibacterial effect, mainly for Gram-negative bacilli. For pregnant women and breastfeeding women are prohibited to use, the dosage according to the instructions on the instructions of different diseases, his dosage is not the same can not be used too much.

Preparation of Levofloxacin heMihydrate.

Product method of Bulk Levofloxacin heMihydrate Powder.

The left-handed components were directly separated from the racemized ofloxacin by HPLC column filled with special stationary phase. Or the amphoteric compound obtained by treating ofloxacin with hydroxylamine sulfate and acidifying with hydrochloric acid is obtained by alkaline ion exchange column treatment. (S)-(+) -mandelic acid is added to form crystallization after salting with (-). The product can be obtained by ion exchange resin and deamination by reduction. Or 2,3,4, 5-tetrafluorobenzoic acid

The raw material is 2-(ethoxymethylene) -3-oxo-3 -(2,3,4, 5-tetrafluorophenyl) propionic acid ethyl ester, then reacts with (S) -2-aminopropanol to introduce asymmetric carbon atoms, and is prepared by closed-loop hydrolysis and introduction of methylpiperazine. In addition, 2,3, -difluoro-6-nitrophenol can react with R-configuration glycidyl p-toluenesulfonate in the presence of phase transfer catalyst to produce optically active compounds, which are then reduced and combined with diethyl ethoxymethylene malonate

(EMME) condensation, and finally through reagent treatment, closed loop, hydrolysis, introduction of piperazine to obtain.